ALPIX Pixium Vision SA

Postponement of the decision on the adoption of a sale plan (plan de cession) and the opening of judicial liquidation proceedings to January 31, 2024

Postponement of the decision on the adoption of a sale plan (plan de cession) and the opening of judicial liquidation proceedings to January 31, 2024

Postponement of the decision on the adoption of a sale plan (plan de cession) and the opening of judicial liquidation proceedings to January 31, 2024

Paris, France, January 17, 2024 – 5:00 pm (CET) – Pixium Vision SA (Euronext Growth Paris - FR001400JX97; Mnemo: ALPIX), a bioelectronics company developing innovative vision systems to enable patients who have lost their sight to live more independent lives, announces that the Paris Commercial Court has postponed its decision on the takeover offer filed on November 20, 2023 and the opening of judicial liquidation proceedings to January 31, 2024.

The Company will apply to Euronext Paris for its shares to be suspended from that date.

Pixium draws investors’ attention to the fact that, given the price offered by the prospective buyer and the Company’s level of indebtedness, the sale proceeds received in the event of a favourable decision by the Commercial Court will not allow a total or partial reimbursement of shareholders.

About Pixium Vision

Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with a surgical intervention and a rehabilitation period. Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners, including some of the most prestigious vision research institutions in the world, such as Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The Company is EN ISO 13485 certified and qualifies as “Entreprise Innovante” by Bpifrance.

For more information:

Follow us on ;

                 

Contacts

Investor Relations



Pixium Vision

Offer Nonhoff

Chief Financial Officer





Media Relations



Rose Piquante Consulting

Sophie Baumont



49

 

Attachment



EN
17/01/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pixium Vision SA

 PRESS RELEASE

Pixium Vision announces the rejection of the sale plan (plan de cessio...

Pixium Vision announces the rejection of the sale plan (plan de cession) by the Court and the conversion of the receivership proceedings into liquidation proceedings Pixium Vision announces the rejection of the sale plan (plan de cession) by the Court and the conversion of the receivership proceedings into liquidation proceedings Paris, France, February 2, 2024 – 02:00 p.m. (CET) – Pixium Vision SA (Euronext Growth Paris - FR001400JX97; Mnemo: ALPIX), a bioelectronics company developing innovative vision systems to enable patients who have lost their sight to live more independent lives, ...

 PRESS RELEASE

Pixium Vision annonce le rejet du plan de cession par le Tribunal et l...

Pixium Vision annonce le rejet du plan de cession par le Tribunal et la conversion de la procédure de redressement judiciaire en liquidation judiciaire Pixium Vision annonce le rejet du plan de cession par le Tribunal et la conversion de la procédure de redressement judiciaire en liquidation judiciaire Paris, France, 2ème février 2024 – 14h00 CET – Pixium Vision SA (Euronext Growth Paris – FR001400JX97 ; Mnemo : ALPIX), société de bioélectronique développant des systèmes de vision innovants pour permettre aux patients ayant perdu la vue de vivre de façon plus autonome, annonce la décision...

 PRESS RELEASE

Postponement of the decision on the adoption of a sale plan (plan de c...

Postponement of the decision on the adoption of a sale plan (plan de cession) and the opening of judicial liquidation proceedings to January 31, 2024 Postponement of the decision on the adoption of a sale plan (plan de cession) and the opening of judicial liquidation proceedings to January 31, 2024 Paris, France, January 17, 2024 – 5:00 pm (CET) – Pixium Vision SA (Euronext Growth Paris - FR001400JX97; Mnemo: ALPIX), a bioelectronics company developing innovative vision systems to enable patients who have lost their sight to live more independent lives, announces that the Paris Commercial...

 PRESS RELEASE

Report de la décision concernant l’arrêté d’un plan de cession et l’ou...

Report de la décision concernant l’arrêté d’un plan de cession et l’ouverture d’une procédure de liquidation judiciaire au 31 janvier 2024 Report de la décision concernant l’arrêté d’un plan de cession et l’ouverture d’une procédure de liquidation judiciaire au 31 janvier 2024 Paris, France, 17 janvier 2024 – 17h00 CET – Pixium Vision SA (Euronext Growth Paris – FR001400JX97 ; Mnemo : ALPIX), société de bioélectronique développant des systèmes de vision innovants pour permettre aux patients ayant perdu la vue de vivre de façon plus autonome, annonce que le Tribunal de Commerce de Paris a ...

 PRESS RELEASE

Postponement of the decision on the adoption of a sale plan (plan de c...

Postponement of the decision on the adoption of a sale plan (plan de cession) and the opening of judicial liquidation proceedings Postponement of the decision on the adoption of a sale plan (plan de cession) and the opening of judicial liquidation proceedings Paris, France, January 17, 2024 – 7:00 am (CET) – Pixium Vision SA (Euronext Growth Paris - FR001400JX97; Mnemo: ALPIX), a bioelectronics company developing innovative vision systems to enable patients who have lost their sight to live more independent lives, announces that the decision of the Paris Commercial Court on the takeover ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch